Clinical Trials

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07477808 2026-03-23

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

116 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

686 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07135882 2025-08-22

PRIME-Lung

420 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07016126 2025-06-11

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Phase 3 Recruiting

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06598527 2025-05-29

SACTION2401

Phase 3 Recruiting

360 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03409614 2025-03-13

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

790 enrolled 2 FDA

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06828757 2025-02-19

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

94 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04866017 2024-10-31

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

63 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT00030771 2024-01-17

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

232 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05157776 2023-05-09

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

72 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02448797 2021-07-20

EVIDENCE

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04951648 2021-07-07

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

220 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03417037 2018-04-30

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02883543 2016-08-30

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

330 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00003387 2016-07-20

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

366 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01342965 2015-02-24

A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

217 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT00535275 2015-02-16

NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00039039 2013-12-18

Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00864331 2013-08-07

Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy

251 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00042302 2012-05-23

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

540 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00042315 2012-05-23

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

490 enrolled